PDF herunterladen
J Neurol Surg B Skull Base 2021; 82(01): 091-095
DOI: 10.1055/s-0040-1722634
Typical Orbital Pathologies
Review Article

Optic Nerve Gliomas

Edward J. Wladis
1   Department of Ophthalmology, Lions Eye Institute, Albany Medical College, Slingerlands, New York, United States
,
Matthew A. Adamo
2   Department of Neurosurgery, Albany Medical College, Slingerlands, New York, United States
,
Lauren Weintraub
3   Division of Hematology/Oncology, Department of Pediatrics, Albany Medical College, Slingerlands, New York, United States
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Objectives To describe the diagnostic and management features of optic nerve gliomas.

Design Literature review.

Results Optic nerve gliomas are generally benign in the pediatric age group although they are usually malignant and aggressive in adults. As such, the mechanisms by which these lesions are diagnosed, the systemic implications, the goals of intervention, and the nature of therapeutic management all differ between these tumors.

Conclusions This article addresses these lesions and discusses the diagnostic and therapeutic paradigms by which they may be approached.

Keywords

glioma - optic nerve glioma - malignant optic nerve glioma

Note

This study specifically focused upon sporadic OPG outlining their clinical characteristics, visual prognosis, and considerations for follow-up and treatment.




Publikationsverlauf

Artikel online veröffentlicht:
19. Januar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Avery RA, Fisher MJ, Liu GT. Optic pathway gliomas. J Neuroophthalmol 2011; 31 (03) 269-278
    CrossrefPubMedGoogle Scholar
  • 2 Beres SJ, Avery RA. Optic pathway gliomas secondary to neurofibromatosis type 1. Semin Pediatr Neurol 2017; 24 (02) 92-99
    CrossrefPubMedGoogle Scholar
  • 3 Beres SJ, Avery RA. Optic pathway gliomas secondary to neurofibromatosis type 1. Semin Pediatr Neurol 2017; 24 (02) 92-99
    CrossrefPubMedGoogle Scholar
  • 4 Czyzyk E, Jóźwiak S, Roszkowski M, Schwartz RA. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 2003; 18 (07) 471-478
    CrossrefPubMedGoogle Scholar
  • 5 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol 2012; 14 (Suppl. 05) v1-v49
    Google Scholar
  • 6 Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol 1994; 38 (05) 427-452
    CrossrefPubMedGoogle Scholar
  • 7 Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol 2017; 28 (03) 289-295
    CrossrefPubMedGoogle Scholar
  • 8 Blanchard G, Lafforgue MP, Lion-François L. et al; NF France network. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 2016; 20 (02) 275-281
    CrossrefPubMedGoogle Scholar
  • 9 Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A 2004; 127A (03) 224-229
    CrossrefPubMedGoogle Scholar
  • 10 Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125 (01) 63-66
    CrossrefPubMedGoogle Scholar
  • 11 Prada CE, Hufnagel RB, Hummel TR. et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr 2015; 167 (04) 851-856.e1
    CrossrefPubMedGoogle Scholar
  • 12 Astrup J. Natural history and clinical management of optic pathway glioma. Br J Neurosurg 2003; 17 (04) 327-335
    CrossrefPubMedGoogle Scholar
  • 13 Chateil JF, Soussotte C, Pédespan JM, Brun M, Le Manh C, Diard F. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 2001; 74 (877) 24-31
    CrossrefPubMedGoogle Scholar
  • 14 Kornreich L, Blaser S, Schwarz M. et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol 2001; 22 (10) 1963-1969
    PubMedGoogle Scholar
  • 15 Hoffman HJ, Soloniuk DS, Humphreys RP. et al. Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. Neurosurgery 1993; 33 (06) 964-971
    PubMedGoogle Scholar
  • 16 Bowers DC, Gargan L, Kapur P. et al. Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol 2003; 21 (15) 2968-2973
    CrossrefPubMedGoogle Scholar
  • 17 Cummings TJ, Provenzale JM, Hunter SB. et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol 2000; 99 (05) 563-570
    CrossrefPubMedGoogle Scholar
  • 18 Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000; 26 (04) 361-367
    CrossrefPubMedGoogle Scholar
  • 19 Lau N, Feldkamp MM, Roncari L. et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59 (09) 759-767
    CrossrefPubMedGoogle Scholar
  • 20 Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005; 65 (07) 2755-2760
    CrossrefPubMedGoogle Scholar
  • 21 Jones DT, Kocialkowski S, Liu L. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68 (21) 8673-8677
    CrossrefPubMedGoogle Scholar
  • 22 Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28 (20) 2119-2123
    CrossrefPubMedGoogle Scholar
  • 23 Friedman JM, Birch P. An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 1997; 28 (02) 131-132
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Revere KE, Katowitz WR, Katowitz JA, Rorke-Adams L, Fisher MJ, Liu GT. Childhood optic nerve glioma: vision loss due to biopsy. Ophthal Plast Reconstr Surg 2017; 33 (3S, Suppl 1): S107-S109
    CrossrefPubMedGoogle Scholar
  • 25 Farazdaghi MK, Katowitz WR, Avery RA. Current treatment of optic nerve gliomas. Curr Opin Ophthalmol 2019; 30 (05) 356-363
    CrossrefPubMedGoogle Scholar
  • 26 Fisher MJ, Loguidice M, Gutmann DH. et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-oncol 2012; 14 (06) 790-797
    Google Scholar
  • 27 Fisher MJ, Avery RA, Allen JC. et al; REiNS International Collaboration. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 2013; 81 (21, Suppl 1): S15-S24
    CrossrefPubMedGoogle Scholar
  • 28 Avery RA, Liu GT, Fisher MJ. et al. Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 2011; 151 (03) 542-9.e2
    CrossrefPubMedGoogle Scholar
  • 29 Fard MA, Fakhree S, Eshraghi B. Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol 2013; 251 (10) 2429-2436
    CrossrefPubMedGoogle Scholar
  • 30 Avery RA, Cnaan A, Schuman JS. et al. Longitudinal change of circumpapillary retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 2015; 160 (05) 944-952.e1
    CrossrefPubMedGoogle Scholar
  • 31 Balcer LJ, Liu GT, Heller G. et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001; 131 (04) 442-445
    CrossrefPubMedGoogle Scholar
  • 32 Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004; 111 (03) 568-577
    CrossrefPubMedGoogle Scholar
  • 33 Wan MJ, Ullrich NJ, Manley PE, Kieran MW, Goumnerova LC, Heidary G. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol 2016; 129 (01) 173-178
    CrossrefPubMedGoogle Scholar
  • 34 Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 2010; 14 (02) 155-158
    CrossrefPubMedGoogle Scholar
  • 35 Packer RJ, Ater J, Allen J. et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86 (05) 747-754
    CrossrefPubMedGoogle Scholar
  • 36 Ater J, Holmes E, Zhou T. et al. Abstracts from the thirteenth international symposium on pediatric neuro-oncology: results of COG protocol A9952—a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro-oncol 2008; 10: 451-452
    PubMedGoogle Scholar
  • 37 Lafay-Cousin L, Sung L, Carret AS. et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008; 112 (04) 892-899
    CrossrefPubMedGoogle Scholar
  • 38 Yu DY, Dahl GV, Shames RS, Fisher PG. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol 2001; 23 (06) 349-352
    CrossrefPubMedGoogle Scholar
  • 39 Massimino M, Spreafico F, Cefalo G. et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002; 20 (20) 4209-4216
    CrossrefPubMedGoogle Scholar
  • 40 Gururangan S, Fisher MJ, Allen JC. et al. Temozolomide in children with progressive low-grade glioma. Neuro-oncol 2007; 9 (02) 161-168
    CrossrefPubMedGoogle Scholar
  • 41 Bouffet E, Jakacki R, Goldman S. et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012; 30 (12) 1358-1363
    CrossrefPubMedGoogle Scholar
  • 42 Lassaletta A, Scheinemann K, Zelcer SM. et al. Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol 2016; 34 (29) 3537-3543
    CrossrefPubMedGoogle Scholar
  • 43 Cappellano AM, Petrilli AS, da Silva NS. et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 2015; 121 (02) 405-412
    CrossrefPubMedGoogle Scholar
  • 44 Fisher M, Balcer L, Gutmann D. et al. Neurofibromatosis Type 1 Associated Optic Glioma Visual Outcomes Following Chemotherapy: An International Multicenter Retrospective Analysis. New York, NY: Oxford University Press, Inc.; 2010
    Google Scholar
  • 45 Fletcher WA, Imes RK, Hoyt WF. Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography. J Neurosurg 1986; 65 (02) 154-159
    CrossrefPubMedGoogle Scholar
  • 46 Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 2010; 46 (12) 2253-2259
    CrossrefPubMedGoogle Scholar
  • 47 Falzon K, Drimtzias E, Picton S, Simmons I. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Br J Ophthalmol 2018; 102 (10) 1367-1371
    CrossrefPubMedGoogle Scholar
  • 48 Banerjee A, Jakacki RI, Onar-Thomas A. et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-oncol 2017; 19 (08) 1135-1144
    CrossrefPubMedGoogle Scholar
  • 49 Hwang EI, Jakacki RI, Fisher MJ. et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013; 60 (05) 776-782
    CrossrefPubMedGoogle Scholar
  • 50 Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 2014; 132 (01) 111-114
    CrossrefPubMedGoogle Scholar
  • 51 Gururangan S, Fangusaro J, Poussaint TY. et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas: a Pediatric Brain Tumor Consortium study. Neuro-oncol 2014; 16 (02) 310-317
    CrossrefPubMedGoogle Scholar
  • 52 Bataini JP, Delanian S, Ponvert D. Chiasmal gliomas: results of irradiation management in 57 patients and review of literature. Int J Radiat Oncol Biol Phys 1991; 21 (03) 615-623
    CrossrefPubMedGoogle Scholar
  • 53 Cappelli C, Grill J, Raquin M. et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child 1998; 79 (04) 334-338
    CrossrefPubMedGoogle Scholar
  • 54 Grabenbauer GG, Schuchardt U, Buchfelder M. et al. Radiation therapy of optico-hypothalamic gliomas (OHG): radiographic response, vision and late toxicity. Radiother Oncol 2000; 54 (03) 239-245
    CrossrefPubMedGoogle Scholar
  • 55 Horwich A, Bloom HJ. Optic gliomas: radiation therapy and prognosis. Int J Radiat Oncol Biol Phys 1985; 11 (06) 1067-1079
    CrossrefPubMedGoogle Scholar
  • 56 Jenkin D, Angyalfi S, Becker L. et al. Optic glioma in children: surveillance, resection, or irradiation?. Int J Radiat Oncol Biol Phys 1993; 25 (02) 215-225
    CrossrefPubMedGoogle Scholar
  • 57 Zeid JL, Charrow J, Sandu M, Goldman S, Listernick R. Orbital optic nerve gliomas in children with neurofibromatosis type 1. J AAPOS 2006; 10 (06) 534-539
    CrossrefPubMedGoogle Scholar
  • 58 Alireza M, Amelot A, Chauvet D, Terrier LM, Lot G, Bekaert O. Poor prognosis and challenging treatment of optic nerve malignant gliomas: literature review and case report series. World Neurosurg 2017; 97: 751.e1-751.e6
    CrossrefPubMedGoogle Scholar
  • 59 Hoyt WF, Meshel LG, Lessell S, Schatz NJ, Suckling RD. Malignant optic glioma of adulthood. Brain 1973; 96 (01) 121-132
    CrossrefPubMedGoogle Scholar
  • 60 Traber GL, Pangalu A, Neumann M. et al. Malignant optic glioma: the spectrum of disease in a case series. Graefes Arch Clin Exp Ophthalmol 2015; 253 (07) 1187-1194
    CrossrefPubMedGoogle Scholar
  • 61 Miller NR. Primary tumours of the optic nerve and its sheath. Eye (Lond) 2004; 18 (11) 1026-1037
    CrossrefPubMedGoogle Scholar